CETP INHIBITION: WHERE NOW?

A position statement by Philip Barter and Kerry-Anne Rye The Heart Research Institute, Sydney, Australia
Read more...

New safety data on CETP inhibitor RO4607381/JJT-705

Data presented at the American College of Cardiology Scientific Sessions, Chicago, March 20-April show that the new cholesteryl ester transfer protein (CETP) inhibitor RO4607381/JJT-705 is well tolerated with no indication of any treatment-related increase in blood pressure. As well, experimental studies in an animal model show that RO4607381/JTT-705 had no impact on blood pressure or rennin-angiotensin system gene expression.
Read more...

New CETP inhibitor shows promise

The second study was designed to investigate the effects of anacetrapib on 24-hour ambulatory blood pressure. Clinical trials with torcetrapib, another CETP inhibitor, had shown significant increases in blood pressure associated with treatment.
Read more...

New data from ILLUMINATE: outcome trial with torcetrapib

New data from the ILLUMINATE trial, published on-line in the New England Journal of Medicine, November 5 do not disprove the hypothesis that CETP inhibition is cardioprotective. Further testing with a different CETP inhibitor that does not share off-target effects of torcetrapib is needed.
Download report...
Download Powerpoint Presentation

OTHER AHA 2007 reports

Download article...

Promising data on new CETP inhibitor

MK-0859, a new cholesteryl ester transfer protein (CETP) inhibitor, produces effective dose-dependent lipid-lowering and is well tolerated.
Download article...

Disappointing results with major studies with torcetrapib

Results from ILLUSTRATE and RADIANCE failed to demonstrate any benefit on progression of atherosclerosis with torcetrapib administered in combination with atorvastatin, despite substantial increases in HDL cholesterol.
Download article...

Results of RADIANCE 2 trial

July 2007 - Administration of torcetrapib did not influence atherosclerosis progression despite substantially raising HDL cholesterol levels, according to the results of the RADIANCE 2 study, published in the Lancet.
Download article...